NASDAQ:TPST Tempest Therapeutics (TPST) Stock Price, News & Analysis $10.02 +0.67 (+7.17%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$10.02 0.00 (0.00%) As of 08/22/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tempest Therapeutics Stock (NASDAQ:TPST) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tempest Therapeutics alerts:Sign Up Key Stats Today's Range$9.35▼$10.1050-Day Range$6.25▼$10.5352-Week Range$5.33▼$20.67Volume42,739 shsAverage Volume108,739 shsMarket Capitalization$44.49 millionP/E RatioN/ADividend YieldN/APrice Target$30.00Consensus RatingModerate Buy Company Overview Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. Read More Tempest Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreTPST MarketRank™: Tempest Therapeutics scored higher than 24% of companies evaluated by MarketBeat, and ranked 846th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingTempest Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageTempest Therapeutics has received no research coverage in the past 90 days.Read more about Tempest Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tempest Therapeutics are expected to grow in the coming year, from ($1.39) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tempest Therapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tempest Therapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTempest Therapeutics has a P/B Ratio of 4.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tempest Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.72% of the float of Tempest Therapeutics has been sold short.Short Interest Ratio / Days to CoverTempest Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tempest Therapeutics has recently increased by 16.11%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTempest Therapeutics does not currently pay a dividend.Dividend GrowthTempest Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.72% of the float of Tempest Therapeutics has been sold short.Short Interest Ratio / Days to CoverTempest Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tempest Therapeutics has recently increased by 16.11%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 2 people have searched for TPST on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tempest Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of Tempest Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 22.52% of the stock of Tempest Therapeutics is held by institutions.Read more about Tempest Therapeutics' insider trading history. Receive TPST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tempest Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TPST Stock News HeadlinesTempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | finanznachrichten.deTempest Therapeutics Advances Clinical Development with Orphan Drug Designations and Pivotal Trial Clearance for Amezalpat and TPST-1495August 11, 2025 | quiverquant.comQHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.August 23 at 2:00 AM | The Oxford Club (Ad)Tempest Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 11, 2025 | globenewswire.comMorpheus-Liver Study: A New Horizon in Advanced Liver Cancer TreatmentAugust 4, 2025 | tipranks.comTempest Therapeutics’ Promising Advances in Liver Cancer TreatmentJuly 3, 2025 | tipranks.comTempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in China - NasdaqJuly 2, 2025 | nasdaq.comTempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in ChinaJune 30, 2025 | globenewswire.comSee More Headlines TPST Stock Analysis - Frequently Asked Questions How have TPST shares performed this year? Tempest Therapeutics' stock was trading at $10.8485 at the beginning of the year. Since then, TPST stock has decreased by 7.6% and is now trading at $10.02. How were Tempest Therapeutics' earnings last quarter? Tempest Therapeutics, Inc. (NASDAQ:TPST) posted its quarterly earnings results on Monday, August, 11th. The company reported ($2.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.23) by $1.16. When did Tempest Therapeutics' stock split? Tempest Therapeutics shares reverse split on Friday, June 25th 2021.The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Tempest Therapeutics' major shareholders? Tempest Therapeutics' top institutional investors include Versant Venture Management LLC (7.33%), Geode Capital Management LLC (0.94%), Group One Trading LLC and Belvedere Trading LLC. Insiders that own company stock include Versant Venture Capital Vi, L, Stephen R Brady, Justin Trojanowski and Samuel Whiting. View institutional ownership trends. How do I buy shares of Tempest Therapeutics? Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tempest Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tempest Therapeutics investors own include Meta Platforms (META), Cloudflare (NET), NVIDIA (NVDA), Snowflake (SNOW), Tesla (TSLA), Intel (INTC) and Pfizer (PFE). Company Calendar Last Earnings8/11/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TPST CIK1544227 Webwww.millendo.com Phone415-798-8589FaxN/AEmployees20Year Founded2012Price Target and Rating Average Price Target for Tempest Therapeutics$30.00 High Price Target$65.00 Low Price Target$9.00 Potential Upside/Downside+199.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($14.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$41.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-334.76% Return on Assets-130.63% Debt Debt-to-Equity RatioN/A Current Ratio2.12 Quick Ratio2.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.20 per share Price / Book4.55Miscellaneous Outstanding Shares4,440,000Free Float4,231,000Market Cap$44.49 million OptionableOptionable Beta-1.93 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:TPST) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.